Company intelligence / Profile preview

Adaptin Bio

Charlotte, North Carolina, United Statesadaptinbio.com ↗

Ownership: Private
Development stage: Other

Overview

Adaptin Bio has developed a proprietary BRiTE technology that enables targeted delivery of therapeutics across the blood-brain barrier. Their lead candidate, APTN‑101 targeting EGFRvIII in glioblastoma, has shown strong preclinical efficacy and safety. In September 2024, the FDA cleared their IND application for APTN‑101 to begin a first-in-human Phase 1 trial in GBM patients. Preclinical data demonstrated high specificity against tumor antigen-expressing glioma cells and significant brain distribution with non-toxicity.

Therapeutic areas: OncologyNeurology
Modalities: Bispecific T cell engagers (BRiTE platform)Engineered polyclonal T cells
Industry: Biotech

Drug pipeline

1 asset

APTN-101

Unknown

Partnerships

Lucius Partners provides strategic support and investment.Laidlaw & Company mentioned as an investor/supporter.No major pharma partnerships publicly announced yet.

Beyond the preview

Go deeper on Adaptin Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adaptin Bio.

Explore the full profile